Department of Cardiovascular Surgery, Faculty of Medicine, University of Miyazaki, 5200 Kiyotakecho Kihara, Miyazaki, Miyazaki, 889-1692, Japan.
Department of Cardiovascular Surgery, Miyazaki Medical Association Hospital, Miyazaki, Miyazaki, Japan.
Heart Vessels. 2021 Jul;36(7):1064-1071. doi: 10.1007/s00380-021-01774-6. Epub 2021 Jan 21.
The objective of this study was to analyze our surgical experiences with mitral valve plasty (MVP) combined with subvalvular procedures (SVPs) for functional mitral regurgitation (FMR) and to determine which preoperative factors affected clinical outcomes.
This study retrospectively analyzed 33 patients who underwent MVP combined with SVPs for FMR with a left ventricular ejection fraction lower than 40% and advanced remodeled left ventricles. The mean follow-up period was 49 ± 33 months.
The preoperative mean right ventricular fractional area change (RVFAC) used to quantify right ventricular (RV) systolic function was 26 ± 11%. Sixteen patients (48%) had an RVFAC < 26%. One patient died during hospital stay, and nine more patients died of cardiac causes during follow-up. The 3- and 5-year rates of freedom from cardiac-related mortality were 78% and 68%, respectively. RVFAC was the significant predictor of cardiac-related mortality in a univariate analysis (risk ratio [RR] = 0.92, 95% confidence interval [CI] 0.85-0.99, p = 0.03) and demonstrated a non-significant tendency to predict cardiac-related mortality in the Cox multivariate analysis (RR = 0.94, 95% CI 0.86-1.003, p = 0.08). Continued reverse left ventricular remodeling was associated with an RVFAC ≥ 26%. At 3 years, there was also a significant difference in survival rates of cardiac-related mortality between patients with an RVFAC ≥ 26% and < 26% (94% vs. 61%; p = 0.03).
Preoperative RV function affected left ventricular remodeling and cardiac-related mortality after MV surgery. MVP combined with SVPs for FMR provided promising results for patients without severe RV dysfunction.
本研究旨在分析我们在二尖瓣成形术(MVP)联合瓣下手术(SVP)治疗功能性二尖瓣反流(FMR)方面的手术经验,并确定哪些术前因素影响临床结果。
本研究回顾性分析了 33 例左心室射血分数(LVEF)低于 40%且左心室重构晚期的 FMR 患者行 MVP 联合 SVP 的临床资料。平均随访时间为 49±33 个月。
术前右心室射血分数(RVFAC)平均值用于量化右心室(RV)收缩功能,为 26±11%。16 例(48%)患者的 RVFAC<26%。1 例患者在住院期间死亡,9 例患者在随访期间因心脏原因死亡。3 年和 5 年免于心脏相关死亡率的比例分别为 78%和 68%。在单因素分析中,RVFAC 是心脏相关死亡率的显著预测因素(风险比 [RR] = 0.92,95%置信区间 [CI] 0.85-0.99,p = 0.03),并且在 Cox 多因素分析中显示出预测心脏相关死亡率的非显著趋势(RR = 0.94,95%CI 0.86-1.003,p = 0.08)。持续的左心室逆重构与 RVFAC≥26%相关。3 年时,RVFAC≥26%与<26%的患者心脏相关死亡率的生存率也存在显著差异(94% vs. 61%;p = 0.03)。
术前 RV 功能影响 MVP 术后左心室重构和心脏相关死亡率。MVP 联合 SVP 治疗 FMR 为无严重 RV 功能障碍的患者提供了有希望的结果。